Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines targeting genetically determined dependencies within the chromatin regulatory system using its Gene Traffic Control platform. Foghorn Therapeutics has a research collaborationsand license agreements with Merck and Loxo Oncology.the company was incorporated in 2015 and is headquartered in Cambridge, MA.